A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients.
P E Greilich, B M Alving, K L O'Neill, A S Chang, T J Reid
Index: Anesth. Analg. 84 , 31-38, (1997)
Full Text: HTML
Abstract
The monoclonal antibody, c7E3 Fab, binds to the platelet surface fibrinogen receptor (GPIIb/IIIa), inhibiting platelet aggregation and clot retraction. We performed an in vitro study to assess the ability of a modification of the thromboelastograph (MTEG) to detect inhibition of clot strength by c7E3 Fab and its reversal with platelet-rich plasma (PRP). In the modified assay (MTEG), thrombin was added to whole blood (WB) and platelet-poor plasma (PPP) and the resultant maximum amplitude (MA) was measured, MAWB and MAPPP, respectively. Anticoagulated blood samples from 17 patients scheduled for cardiac surgery were collected for a dose response (Part I; n = 5) and c7E3 Fab reversal (Part II; n = 12) study. Clot strength was reduced in a dose-dependent manner by c7E3 Fab. Ecteola cellulose effectively reversed the effect of heparin on the thrombin time and the addition of PRP significantly increased the MAWB (P < 0.0001) and MAWP-PPP (P < 0.0001). Subtracting the MAPPP from MAWB significantly magnified the response of MA to the addition of c7E3 Fab (P = 0.002) and its reversal with PRP (P = 0.005). This in vitro study indicates that the MTEG is a responsive assay demonstrating that inhibition by the antiplatelet c7E3 Fab is reversible with PRP.
Related Compounds
Related Articles:
Optimized Treatment of Heparinized Blood Fractions to Make Them Suitable for Analysis.
2015-08-01
[Biopreserv. Biobank. 13 , 287-95, (2015)]
2001-12-25
[J. Chromatogr. B. Biomed. Sci. Appl. 765 , 151-160, (2001)]
1992-03-31
[Clin. Chim. Acta 206 , 167-180, (1992)]
1990-02-19
[Thromb. Haemost. 63(1) , 16-23, (1990)]
1993-08-01
[Blood Coagul. Fibrinolysis 4(4) , 635-8, (1993)]